|Bid||0.00 x 800|
|Ask||0.00 x 1100|
|Day's range||8.10 - 9.05|
|52-week range||6.97 - 39.49|
|Beta (5Y monthly)||0.89|
|PE ratio (TTM)||N/A|
|Earnings date||21 Feb 2022 - 25 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||15.91|
Investors need to pay close attention to Esperion Therapeutics (ESPR) stock based on the movements in the options market lately.
- Analysis of pooled Phase 3 data showed that NEXLETOL [bempedoic acid (BA)] alone lowered LDL-C levels comparable to that of a moderate- or high-intensity statin (≥ 30%) in nearly 1 out of 3 of patients - - In patients with metabolic syndrome NEXLETOL lowered hemoglobin A1c (HbA1c), fasting plasma glucose and low-density lipoprotein cholesterol (LDL-C), at week 12 - - In healthy patients treatment with BA reduced fasting LDL-C, non- high-density lipoprotein cholesterol (HDL-C), and baseline hig
Esperion Therapeutics, Inc. ( NASDAQ:ESPR ) is possibly approaching a major achievement in its business, so we would...